EQ504, a Potent AhR Modulator, Promotes Epithelial Repair and Barrier Restoration Compared to Clinically Validated AhR Agonists<span>Mary Casis, et al.</span><span> American Association of Immunology Conference </span><span>2026</span>

close disclaimer Cookies on this website. We use cookies on Equillium to provide you with the best possible experience. If you wish to review the cookies we store, please select the Cookie Preferences option on this banner. After your preferences are saved, you can use the cookie icon at the left to modify your selections at any time. For more information, you can review our Privacy Notice . Accept Cookie Preferences No, thanks close preference sidebar Equillium Cookie Preferences Please use the following sections to learn more about the types of cookies we use, and how you can opt out of those you do not wish to be stored. At https://www.equilliumbio.com, we respect your privacy and are committed to protecting your information. For more information, you can review our Privacy Notice . Accept Recommended Settings Necessary Cookies These cookies are necessary for the services and viewing experience of this site, and cannot be opted out of via this tool. If you still wish to remove these, you may do using your browser settings. A description of these technologies is provided in our Privacy Notice . Search query Home Company expand Back About Us Executive Team Board of Directors Scientific & Clinical Advisors Partners Pipeline Technology expand Back EQ504 EQ302 Publications Presentations Investors expand Back Investor Overview Stock Information expand Investors Stock Chart Analyst Coverage Press Releases Events & Presentations Email Alerts & Contacts SEC Filings Corporate Governance expand Investors Governance Documents Committee Composition Investor FAQs Careers Contact Us Skip to main content Home Company About Us Executive Team Board of Directors Scientific & Clinical Advisors Partners Pipeline Technology EQ504 EQ302 Publications Presentations Investors Investor Overview Stock Information Stock Chart Analyst Coverage Press Releases Events & Presentations Email Alerts & Contacts SEC Filings Corporate Governance Governance Documents Committee Composition Investor FAQs Careers Contact Us Home Company expand Company Learn more about a top-tier immunobiology company advancing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need About Us Executive Team Board of Directors Scientific & Clinical Advisors Partners Pipeline Technology expand Our Technology Learn more about our technology targeting immune-inflammatory pathways EQ504 EQ302 Publications Presentations Investors expand Our Patients Learn more about autoimmune and inflammatory disorders and our commitment to transform the lives of the patients and families affected by them Investor Overview Stock Information Stock Chart Analyst Coverage Press Releases Events & Presentations Email Alerts & Contacts SEC Filings Corporate Governance Governance Documents Committee Composition Investor FAQs Careers Contact Us Search query Search Search query Search Presentation Details NASD: EQ 2.59 + 0.09 ( 3.60% ) 20 minutes minimum delay | July 17, 2026 4:00 PM Back EQ504, a Potent AhR Modulator, Promotes Epithelial Repair and Barrier Restoration Compared to Clinically Validated AhR Agonists 04/20/2026 Download this Press Release PDF Format (opens in new window) Mary Casis, et al. Conference: American Association of Immunology Conference Year: 2026 Stay Connected Stay Connected © 2026 Equillium Bio. - All rights reserved Privacy Notice Cookies Policy Powered By Q4 Inc. 5.183.0.4 (opens in new window)